Cheng, Yuan; Qin, Shu-kui; Li, Jin; Dai, Guang-hai; Shen, Bai-yong; Ying, Jie-er; Ba, Yi; Liang, Han; Wang, Xin-bo; Xu, Ye; Zhou, Lin; Ding, Ke-feng; Qin, Yan-ru; Yang, Shu-jun; Guan, Wen-xian; Zheng, Hui; Wang, Qian; Song, Hang; Zhu, Yan-ping published the artcile< A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX)>, Formula: C20H21CaN7O7, the main research area is medication gastrointestinal carcinoma human tumor xenograft clin study; Advanced gastrointestinal carcinomas; Clinical study; Patient-derived tumor xenograft; Personalized medication.
Establish patient-derived tumor xenograft (PDTX) from advanced GICs and assess the clin. value and applicability of PDTX for the treatment of advanced gastrointestinal cancers. Patients with advanced GICs were enrolled in a registered multi-center clin. study (ChiCTR-OOC-17012731). The performance of PDTX was evaluated by analyzing factors that affect the engraftment rate, comparing the histol. consistency between primary tumors and tumorgrafts, examining the concordance between the drug effectiveness in PDTXs and clin. responses, and identifying genetic variants and other factors associated with prognosis. Thirty-three patients were enrolled in the study with the engraftment rate of 75.8% (25/33). The success of engraftment was independent of age, cancer types, pathol. stages of tumors, and particularly sampling methods. Tumorgrafts retained the same histopathol. characteristics as primary tumors. Forty-nine regimens involving 28 drugs were tested in seventeen tumorgrafts. The median time for drug testing was 134.5 days. Follow-up information was obtained about 10 regimens from 9 patients. The concordance of drug effectiveness between PDTXs and clin. responses was 100%. The tumor mutation burden (TMB) was correlated with the effectiveness of single drug regimens, while the outgrowth time of tumorgrafts was associated with the effectiveness of combined regimens. The engraftment rate in advanced GICs was higher than that of other cancers and meets the acceptable standard for applying personalized therapeutic strategies. Tumorgrafts from PDTX kept attributes of the primary tumor. Predictions from PDTX modeling closely agreed with clin. drug responses. PDTX may already be clin. applicable for personalized medication in advanced GICs.
Journal of Cancer Research and Clinical Oncology published new progress about Aging, animal. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Formula: C20H21CaN7O7.
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts